A Phase 2b, Double-Blind, Placebo-Controlled, Multinational, Multicenter, Randomized Study Evaluating the Safety and Efficacy of Intracoronary Administration of MYDICAR (AAV1/SERCA2a) in Subjects With Heart Failure

Trial Profile

A Phase 2b, Double-Blind, Placebo-Controlled, Multinational, Multicenter, Randomized Study Evaluating the Safety and Efficacy of Intracoronary Administration of MYDICAR (AAV1/SERCA2a) in Subjects With Heart Failure

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Jun 2016

At a glance

  • Drugs SERCA 2a gene therapy (Primary)
  • Indications Heart failure
  • Focus Registrational; Therapeutic Use
  • Acronyms CUPID-2; CUPID-2b
  • Sponsors Celladon
  • Most Recent Events

    • 23 Mar 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 20 Jan 2016 Results published in the Lancet.
    • 26 Jun 2015 According to a Celladon Corporation media release, company has announced the suspension of its plans for research or development of MYDICAR program.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top